EVERYTHING ABOUT HEMGENIX

Quantity of suitable patients: CDEC reviewed the uncertainty in the quantity of people with reasonably intense to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some sufferers who are classified as getting mild or moderate disease might have a extreme bleeding ph